Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines

Bušić, Nikolina; Lucijanić, Tomo; Baršić, Bruno; Lukšić, Ivica; Bušić, Iva; Kurdija, Goran; Barbić, Ljubo; Kunstek, Sanja; Jelic, Tea; Lucijanić, Marko

doi:10.1002/jmv.27666

Cited by 24 publications

(36 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of vaccinated patients who required hospitalization due to COVID-19 were elderly with a high comorbidity burden thus being unable to develop a proper immune response following vaccination [ 128 ].…”

Section: Characteristics Of Available Vaccinesmentioning

confidence: 99%

COVID-19 2022 update: transition of the pandemic to the endemic phase

et al. 2022

View full text Add to dashboard Cite

COVID-19, which is caused by the SARS-CoV-2, has ravaged the world for the past 2 years. Here, we review the current state of research into the disease with focus on its history, human genetics and genomics and the transition from the pandemic to the endemic phase. We are particularly concerned by the lack of solid information from the initial phases of the pandemic that highlighted the necessity for better preparation to face similar future threats. On the other hand, we are gratified by the progress into human genetic susceptibility investigations and we believe now is the time to explore the transition from the pandemic to the endemic phase. The latter will require worldwide vigilance and cooperation, especially in emerging countries. In the transition to the endemic phase, vaccination rates have lagged and developed countries should assist, as warranted, in bolstering vaccination rates worldwide. We also discuss the current status of vaccines and the outlook for COVID-19.

show abstract

Section: Characteristics Of Available Vaccinesmentioning

confidence: 99%

COVID-19 2022 update: transition of the pandemic to the endemic phase

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A total of 1446 (55.9%) patients were men. The median Charlson comorbidity index was 4, IQR (2)(3)(4)(5). Severe or critical COVID-19 symptoms on admission were present in 1956 (75.6%) patients.…”

Section: Patients' Characteristicsmentioning

confidence: 99%

“…Up to 15%-20% of pre-vaccination patients were hospitalized due to respiratory insufficiency or active comorbidities that required hospital care ( 2 ). Many people still remain unvaccinated, presenting a high risk group for short-term mortality ( 3 ). Elderly patients and those burdened with comorbidities are especially susceptible to unfavorable clinical course during hospital stay ( 4 ).…”

mentioning

confidence: 99%

Survival after hospital discharge in patients hospitalized for acute coronavirus disease 2019: data on 2586 patients from a tertiary center registry

Lucijanić

Živković²,

Zelenika³

et al. 2022

Croat Med J

View full text Add to dashboard Cite

Aim To assess the long-term survival after hospital discharge of patients hospitalized due to coronavirus disease 2019 .Methods We retrospectively reviewed data on post-discharge survival of 2586 COVID-19 patients hospitalized in our tertiary hospital from March 2020 to March 2021. ResultsAmong 2586 patients, 1446 (55.9%) were men. The median age was 70 years, interquartile range (IQR, 60-80). The median Charlson comorbidity index was 4 points, IQR (2-5). The median length of hospital stay was 10 days, IQR (7-16). During a median follow-up of 4 months, 192 (7.4%) patients died. The median survival time after hospital discharge was not reached, and 3-month, 6-month, and 12-month survival rates were 93%, 92%, and 91%, respectively. In a multivariate analysis, mutually independent predictors of worse mortality after hospital discharge were age >75 years, Eastern Cooperative Oncology Group status 4, white blood cell count >7 ×10 9 /L, red cell distribution width >14%, urea on admission >10.5 mmol/L, mechanical ventilation during hospital stay, readmission after discharge, absence of obesity, presence of chronic obstructive pulmonary disease, dementia, and metastatic malignancy (P < 0.05 for all).Conclusion Substantial risk of death persists after hospital admission due to COVID-19. Factors related to an increased risk are older age, higher functional impairment, need for mechanical ventilation during hospital admission, parameters indicating more pronounced inflammation, impaired renal function, and particular comorbidities. Interventions aimed at improving patients' functional capacity may be needed.

show abstract

“…For preexposure prophylaxis, the monoclonal antibody combinations of tixagevimab plus cilgavimab also have an EUA from the FDA for populations who are immunocompromised and with limited expected response to vaccination [13]. This is important because unvaccinated and immunocompromised patients are at most risk for severe COVID-19 including ARDS [14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19

et al. 2022

View full text Add to dashboard Cite

Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has created a global pandemic infecting over 230 million people and costing millions of lives. Therapies to attenuate severe disease are desperately needed. Cenicriviroc (CVC), a C-C chemokine receptor type 5 (CCR5) and C-C chemokine receptor type 2 (CCR2) antagonist, an agent previously studied in advanced clinical trials for patients with HIV or nonalcoholic steatohepatitis (NASH), may have the potential to reduce respiratory and cardiovascular organ failures related to COVID-19. Inhibiting the CCR2 and CCR5 pathways could attenuate or prevent inflammation or fibrosis in both early and late stages of the disease and improve outcomes of COVID-19. Clinical trials using CVC either in addition to standard of care (SoC; e.g., dexamethasone) or in combination with other investigational agents in patients with COVID-19 are currently ongoing. These trials intend to leverage the anti-inflammatory actions of CVC for ameliorating the clinical course of COVID-19 and prevent complications. This article reviews the literature surrounding the CCR2 and CCR5 pathways, their proposed role in COVID-19, and the potential role of CVC to improve outcomes.

show abstract

Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines

Cited by 24 publications

References 14 publications

COVID-19 2022 update: transition of the pandemic to the endemic phase

COVID-19 2022 update: transition of the pandemic to the endemic phase

Survival after hospital discharge in patients hospitalized for acute coronavirus disease 2019: data on 2586 patients from a tertiary center registry

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19

Contact Info

Product

Resources

About